Rakuten Medical, Inc. (Rakuten Medical) announced they have entered a multi-year deal with Merck KGaA, Darmstadt, Germany under which Merck KGaA, Darmstadt, Germany will provide cetuximab to Rakuten Medical for its ASP-1929 program. Rakuten Medical uses cetuximab in an intermediate form as the antibody component in its product candidate ASP-1929, an investigational antibody-dye conjugate being studied for the treatment of recurrent, locoregional head and neck cancers. Under this agreement, Rakuten Medical may use cetuximab to produce ASP-1929 for clinical trials and commercial sales. Read more…